Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its…
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
November 21, 2025 16:30 ET Â | Source: Olema Oncology SAN FRANCISCO, Nov.…
MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as…
KX-826: Redefining Confidence with Visible Hair Revival
HongKong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- For millions struggling with thinning…
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
November 11, 2025 20:40 ET Â | Source: Centessa Pharmaceuticals plc BOSTON and…
BPGbio Appoints John Dvor as Executive Vice President, Corporate Development
BOSTON, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered,…
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
November 10, 2025 21:56 ET Â | Source: Vor Biopharma BOSTON, Nov. 10,…
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
November 08, 2025 17:13 ET Â | Source: Intellia Therapeutics, Inc. Deep, stable…
Belite Bio Announces UKs Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
November 02, 2025 09:00 ET Â | Source: Belite Bio, Inc MHRA response…